

Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026

<https://marketpublishers.com/r/GA8875AACADEEN.html>

Date: April 2021

Pages: 275

Price: US\$ 2,400.00 (Single User License)

ID: GA8875AACADEEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026” Report Highlights:

Global Peptide Cancer Vaccine Market Trends Insight

Global Peptide Cancer Drugs Market Opportunity: >USD 20 Billion

Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase

Number Of Peptide Vaccines In Pipeline: >90

Application of Peptide Cancer Vaccine Against Major Cancer

The developments of vaccines have shown incredible impact on human health system and have resulted in significant decrease in mortality rates from several diseases. Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management. In recent times, researchers have exploited the use of vaccines to generate anti-tumor response in management of cancer.

The rapid approval of Provenge for the management of pancreatic cancer and the robust response in market has surged the development of more targeted vaccines in

cancer. In recent times, peptides have emerged as a potential vaccine candidate owing to their small size, simple and cost efficient production and development process. Moreover, peptides are recognized to be highly specific and efficacious, safe and well tolerated. Given their attractive physical and chemical properties, researchers have developed several peptide based vaccines in management of wide range of cancers.

Currently, GV1001 (Riavaxtm, Tertomotide) is the only peptide based vaccine approved for the management of pancreatic cancer in Korea. , GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT). Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells. The vaccine is currently under clinical trials and applications to gain approval in other countries.

Apart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response. Most of the drugs are present in the phase I and II clinical trials which suggests that the market will be flourished with several vaccines targeting different cancers in next 4-5 years. Moreover, in near future the market will see combination of vaccines along with other conventional drugs to improve their efficacy and specificity in targeting the complexity of cancer cells.

Keeping in mind the high adoption rates of the novel therapeutics in North America, it is expected that the region will dominate the global peptide cancer vaccine market for next few years. The high prevalence of cancer and the rising initiatives by government as well as private sectors will also propel the growth of peptide cancer vaccines in this area. In addition to this, Europe and Asia Pacific will also emerge as a potential market wing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector.

As per “Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026” report findings, it is estimated that the global peptide cancer vaccine will follow trajectory growth rates. The market will be favored by the advancement in science and arrival of novel technologies which will further enable the identification of potential targets in developing cancer vaccines. The arrival of peptide based cancer vaccine has caused prompting effects on the overall cancer therapy market and has helped it to make through all the challenges that have been on the way of becoming the most dominant market in the industry.

Contents

1. INTRODUCTION TO PEPTIDE CANCER VACCINE

2. NEED OF PEPTIDE VACCINES

- 2.1 Why Peptides – More Desirable
- 2.2 Peptide Vaccines V/S Traditional Vaccines

3. CLASSIFICATION OF PEPTIDE VACCINES

- 3.1 On the Basis of Sources Obtained
- 3.2 On the Basis of Length
- 3.3 On the Basis of Epitopes

4. MECHANISM OF ACTION OF PEPTIDE CANCER VACCINES

- 4.1 Immunological Cells Activated by Peptide Cancer Vaccines
- 4.2 Procedure of Synthetic Peptide Vaccine Development

5. CLINICAL TRIALS EFFICACY STUDY OF SYNTHETIC PEPTIDE ANALOG OBTAINED FROM WT1 ONCOPROTEIN AGAINST ACUTE MYELOID LEUKEMIA

- 5.1 Basic Layout of the Study
- 5.2 Introduction to WT1 Peptide
- 5.3 Methodologies Involved In the Clinical Study
- 5.4 Results of the Clinical Trial Study

6. WIDE SPECTRUM ACTION OF PEPTIDE CANCER VACCINES AGAINST MAJOR CANCER

- 6.1 Colorectal Cancer
- 6.2 Lung Cancer
- 6.3 Pancreatic Cancer
- 6.4 Gastric Cancer
- 6.5 Prostate Cancer
- 6.6 Breast Cancer

7. GLOBAL PEPTIDE CANCER VACCINE MARKET OVERVIEW

8. GLOBAL PEPTIDE CANCER VACCINE MARKET TRENDS

- 8.1 Optimized Cryptic Peptides
- 8.2 Therapeutic CpG Peptide-Based Cancer Vaccine
- 8.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides
- 8.4 Recombinant Peptide Vaccine
- 8.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines

9. GLOBAL PEPTIDE CANCER VACCINE PIPELINE OVERVIEW

- 9.1 By Country
- 9.2 By Company
- 9.3 By Patient Segment
- 9.4 By Phase

10. GLOBAL PEPTIDE CANCER VACCINE CLINICAL TRIALS INSIGHT

- 10.1 Research
- 10.2 Preclinical
- 10.3 Phase-I
- 10.4 Phase-I/II
- 10.5 Phase-II
- 10.6 Phase-III

11. LUCAVAX – FIRST COMMERCIALY AVAILABLE PEPTIDE CANCER VACCINE

12. GLOBAL PEPTIDE CANCER VACCINE MARKET DYNAMICS

- 12.1 Market Driving Factors
- 12.2 Challenges Ahead For Peptide Cancer Vaccine Market Development

13. PEPTIDE CANCER VACCINE: PROMISING CANDIDATE OF CANCER IMMUNOTHERAPY

- 14. Competitive Landscape
 - 14.1 Enzo Life Science (Alexis Biotech)
 - 14.2 Antigen Express
 - 14.3 BioLife Science

- 14.4 Immatics Biotechnologies
- 14.5 Immune Design
- 14.6 Imugene
- 14.7 Immunomedics
- 14.8 ISA Pharmaceuticals
- 14.9 Galena Biopharma
- 14.10 Generex Biotechnology Corporation
- 14.11 Lytix Biopharma
- 14.12 Merck (Merck Serono)
- 14.13 OncoTherapy Science
- 14.14 Oncothyreon
- 14.15 Pfizer
- 14.16 Phylogica
- 14.17 Symphogen (Receptor BioLogix)
- 14.18 Sumitomo Dainippon Pharma
- 14.19 TapImmune
- 14.20 Vaxon Biotech

List Of Figures

LIST OF FIGURES

- Figure 1-1: Advantages of Peptide Cancer Vaccines
- Figure 2-1: Peptides - Amino Acid & Proteins
- Figure 2-2: Diversification of Vaccines
- Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines
- Figure 3-1: Classification of Peptide Vaccine by Source
- Figure 3-2: Classification on Basis of Length
- Figure 3-3: On the Basis of Epitopes
- Figure 4-1: Immunological Cells Activated By Peptide Cancer Vaccines
- Figure 4-2: Procedure of Synthetic Peptide Cancer Vaccine Development
- Figure 4-3: Determination of Antigen Components, Its Selection & Construction
- Figure 4-4: Role of Adjuvants in Peptide Cancer Vaccines
- Figure 4-5: Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine
- Figure 5-1: Clinical Trial Study of WT1 Peptide Vaccine for Acute Myeloid Leukemia Patients
- Figure 5-2: WT1 Peptide as a Marker for Cancer Therapy
- Figure 5-3: Methodologies Involved In the Clinical Study
- Figure 6-1: Peptides & Colorectal Cancer
- Figure 6-2: Peptides & Lung Cancer
- Figure 6-3: Peptides & Pancreatic Cancer
- Figure 6-4: Peptides & Gastric Cancer
- Figure 6-5: Peptides & Prostate Cancer
- Figure 6-6: Peptides & Breast Cancer
- Figure 7-1: Global – Peptide Therapeutic Market Size (US\$ Billion), 2018 - 2026
- Figure 7-2: Global – Total Peptide Therapeutic Market Size vs. Oncological Peptide Therapeutic Market Size (US\$ Billion), 2012-20
- Figure 7-3: Global – Oncological Peptide Therapeutics Market Share in Total Peptide market (%), 2020
- Figure 7-4: Global – Peptide Oncology Drugs Market Size (US\$ Billion), 2018 - 2026
- Figure 7-5: Peptide Oncology Market – Regional Market Share (%), 2019
- Figure 8-1: Optimized Cryptic Peptides
- Figure 8-2: Therapeutic CpG Peptide-Based Cancer Vaccine
- Figure 8-3: Personalized Neoantigen Vaccination with Synthetic Long Peptides
- Figure 8-4: Recombinant Peptide Vaccine
- Figure 8-5: p53 Peptide-Pulsed Dendritic Cells Cancer Vaccine

Figure 9-1: Global - Peptide Cancer Vaccine in Clinical Pipeline by Country, 2021 till 2026

Figure 9-2: Global - Peptide Cancer Vaccine in Clinical Pipeline by Company, 2021 till 2026

Figure 9-3: Global - Peptide Cancer Vaccine in Clinical Pipeline by Patient Segment, 2021 till 2026

Figure 9-4: Global - Peptide Cancer Vaccine in Clinical Pipeline by Phase, 2021 till 2026

Figure 12-1: Market Drivers of Peptide Cancer Vaccines

Figure 12-2: Peptide Cancer Vaccine: An Active Immunotherapy

Figure 12-3: Peptide Cancer Vaccine: A Personalized, Targeted Therapy

Figure 12-4: Peptide Cancer Vaccine: Highly Efficient, High Immunogenic Response Generating

Figure 12-5: Peptide Cancer Vaccine: Multiple Tumors Targeting Ability

Figure 12-6: Peptide Cancer Vaccine: A Viable Solution to Immunotolerance

Figure 12-7: Peptide Cancer Vaccine: Improves the Quality Of Life & is Cost Effective

Figure 12-8: Challenges of Peptide Cancer Vaccine: The Parameters Related To the Clinical Trials

Figure 12-9: Single Antigen Based Peptide Vaccine: Highly Prone To Failure

Figure 12-10: Lack of Standardized Parameters for Assessing the Result of Clinical Trials

Figure 12-11: Variable Therapeutic Window for Different Patients

Figure 12-12: Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape

Figure 14-1: Enzo Life Science Pipeline

Figure 14-2: Immatics Biotechnologies Pipeline

Figure 14-3: Immune Design Pipeline

Figure 14-4: Imugene Pipeline

Figure 14-5: ISA Pharmaceuticals Pipeline

Figure 14-6: Galena Biopharma Pipeline

Figure 14-7: Generex Biotechnology Pipeline

Figure 14-8: Lytix Biopharma Pipeline

Figure 14-9: Merck Clinical Pipeline

Figure 14-10: Onco Therapy Science Pipeline

Figure 14-11: Oncothyreon Pipeline

Figure 14-12: Sumitomo Dainippon Pharma Pipeline

Figure 14-13: Tapimmune Pipeline

Figure 14-14: Vaxon Biotech Pipeline

I would like to order

Product name: Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/GA8875AACADEEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA8875AACADEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970